Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues - Fierce Biotech
Eli Lilly is acquiring three vaccine developers for up to $3.8B, part of a broader ~$20B M&A spree to build an infectious disease portfolio. The deal signals Lilly is deploying GLP-1 cash flows into pipeline diversification, raising both excitement about strategic optionality and concern about capital allocation discipline.
What happened
Eli Lilly is acquiring three vaccine developers for up to $3.8B, part of a broader ~$20B M&A spree to build an infectious disease portfolio.
The read · May 26
Fade the LLY pop short-term — consensus is already Buy-heavy, insiders are selling, and $20B in M&A spending raises integration risk without near-term EPS catalyst.
Wrong if
LLY re-accelerates GLP-1 revenue guidance or an acquired asset shows near-term clinical readout that validates the deal premium, sending shares sharply higher and stopping out the short.
CoverageSource: Google News · Published here TUE, MAY 26 · 7:57 AM ET · the only report in this recordHow this is decided →
The chart · LLYTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
LLY is up 2.1% on the headline, but the enrichment data argues against chasing. Consensus is already 19 Buys / 11 Strong Buys with only 1 Sell — the street is packed long. Insiders have 2 sells and zero buys in the last 30 days, a quiet bearish signal. A $20B M&A spree in vaccines is a strategic pivot away from the GLP-1 growth story the market is paying peak multiples for; capital deployment into unproven infectious disease assets introduces dilution risk and integration overhead before any revenue contribution.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
2-4 weeks tactical. Follow to be told when one lands.
Receipts
Google News — the original7:57 AM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →